Abstract 8507

Article

Benefit of rituximab combined to ACVBP (R-ACVBP) over ACVBP in 209 poor- risk DLBCL patients treated with up-front consolidative autotransplantation: A GELA phase II trial (LNH 2003-3)

Benefit of rituximab combined to ACVBP (R-ACVBP) over ACVBP in 209 poor- risk DLBCL patients treated with up-front consolidative autotransplantation: A GELA phase II trial (LNH 2003-3)

N. Mounier, C. Gisselbrecht, O. Fitoussi, et al

Methods: This phase II study included 209 poor-risk diffuse large B-cell lymphoma (DLBCL) patients < 60 years (median age 49) with 2 or 3 age-adjusted International Prognostic Index (IPI) factors. Of these, 58% presented with IPI 3-5 (93% with elevated LDH and 54% with extranodal sites > 1). Four cycles of an R-ACVBP regimen was given every 15 days. Complete response and partial response patients received a consolidative BEAM regimen and peripheral blood stem cell rescue.

Results: The complete response rate (CR/CRu) after induction in 176 patients was 61%, and the partial response rate (PR) was 24%, for an ORR of 85%. For the autotransplantation population (n = 175), CR/CRu was 73% and PR was 11 (84%). Three-year progression-free survival and overall survival (PFS and OS) were estimated at 76% and 81%, respectively.

A case-controlled study matching the present R-ACVBP population with ACVBP patients selected from the LNH-98-3 trial showed 3-year PFS to be higher in the R-ACVBP group than among ACVBP patients (75% vs 58%, P = .0003). Three-year OS was estimated at 78% vs 67%, respectively (P = .05). The gain in 3-year OS was significant in patients who received auto transplantation: 89% vs 77% (P = .02).

Conclusions: These results with R-ACVBP induction and consolidative autotransplantation suggest a major survival benefit. A confirmatory prospective study is needed.

Recent Videos
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides
Experts from Vanderbilt University Medical Center emphasize gathering a second opinion to determine if a tumor is resectable in patients with pancreatic cancer.
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Experts from Vanderbilt University Medical Center discuss the use of intraoperative radiation therapy in a 64-year-old patient with pancreatic cancer.
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Related Content